141. Ruxolitinib vs triamcinolone - Topical tofacitinib for LPP/FFA - Locus of control in AD - Low-dose naltrexone for LPP/FFA - Alternative/complementary treatments for HSV

Ruxolitinib vs triamcinolone -

Topical tofacitinib for LPP/FFA -

Locus of control in AD -

Low-dose naltrexone for LPP/FFA -

Alternative/complementary treatments for HSV -

Want to donate to the cause? Do so here!

Donate to the podcast: uofuhealth.org/dermasphere

Check out our video content on YouTube:

www.youtube.com/@dermaspherepodcast

and VuMedi!: www.vumedi.com/channel/dermasphere/

The University of Utah's Dermatology

ECHO: ⁠physicians.utah.edu/echo/dermatology-primarycare -

⁠ Connect with us!

- Web: ⁠dermaspherepodcast.com/⁠ - Twitter: @DermaspherePC

- Instagram: dermaspherepodcast

- Facebook: www.facebook.com/DermaspherePodcast/

- Check out Luke and Michelle’s other podcast,

SkinCast! ⁠healthcare.utah.edu/dermatology/skincast/⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our

friends at:

- ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)

- ⁠www.levelex.com/games/top-derm⁠ (A free dermatology game to learn

more dermatology!